+9,834.6%
CRS vs GSK
+1,657.0%
+8,177.6%
-84.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1990-01-01 to 2026-09-08.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.5% | -2.7% | -0.8% | -2.6% |
| 7D | -3.1% | -4.2% | +1.1% | -1.6% |
| 30D | -19.6% | -7.5% | -12.1% | -17.4% |
| 3M | -8.1% | -3.3% | -4.8% | -7.3% |
| 6M | +18.6% | -9.3% | +27.9% | +22.5% |
| YTD | +45.9% | +1.6% | +44.3% | +44.3% |
| 1Y | +82.5% | +25.5% | +57.0% | +67.0% |
| 3Y | +648.9% | +49.3% | +599.6% | +526.8% |
| 5Y | +1,438.1% | +46.7% | +1,391.5% | +1,178.0% |
| 10Y | +1,327.0% | +76.8% | +1,250.2% | +1,016.0% |
| All | +9,834.6% | +1,657.0% | +8,177.6% | +5,154.7% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1990-01-01 to 2026-09-08: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1990-01-01 to 2026-09-08 analysis · Full analysis span regression · 6 months rolling